In fact, with the exception of the lowest treatment dose investigated (2.5 mg oral semaglutide), almost 100% of patients experienced a reduction in HbA 1c in the phase II trial, indicating that the variability in semaglutide exposure is not likely to affect the proportion of subjects with a clinically relevant treatment response [10]
Both tirzepatide and semaglutide (active ingredients of Mounjaro and Ozempic) are prescription medications approved by the Central Drugs Standard Control Organisation (CDSCO) and are prescribed under medical supervision 5 , 6
Its defined structure and stability make it suitable for in-vitro and preclinical research models where reproducibility and consistency are essential
Bernal, J
Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG , Gibbons DL, Wistuba II, William WN Jr, Heymach JV